Bristol-Myers Squibb Co. said its board elected Michael Bonney, Julia Haller and Phyllis Yale to serve as independent directors.
The appointments are effective at the closing of the New York-based drugmaker's $95 billion acquisition of Celgene Corp. Bonney and Haller are members of Celgene's board.
The addition of the new directors will increase the size of Bristol-Myers' board.
Bonney previously served as CEO and chairman of Kaleido BioSciences Inc. and currently serves as executive chair of the company's board. Haller is the ophthalmologist-in-chief of Wills Eye Hospital in Philadelphia, a position she has held since 2007.
Yale is an advisory partner with Bain & Co.
